Answers are grounded in this paper and cite their sources.
This study reveals molecular subtypes of endometrial cancer through immunohistochemical analysis, highlighting potential treatment implications.
Purpose: This study investigates the molecular characteristics of grade 3 endometrioid endometrial carcinoma (EC) through immunohistochemical analysis of mismatch repair (MMR) proteins and p53, correlating molecular subtypes with clinicopathological features and survival outcomes. Materials and Methods: We retrospectively analyzed 33 patients with surgically staged grade 3 endometrioid EC. Immunohistochemical analysis was performed to assess MMR protein (MLH1, MSH2, MSH6, PMS2) and p53 expression. Cases were classified into MMR-deficient (MMRd), p53 wild-type (p53wt), and p53 abnormal (p53abn) molecular subtypes. A comparative analysis was conducted on clinicopathological characteristics and survival outcomes across molecular subgroups. Results: The molecular subtype distribution was: MMRd (36.4%), p53abn (15.2%), and p53wt (48.5%). Clinicopathological features, including age, stage, myometrial invasion, lymph node metastasis, and lymphovascular space invasion did not significantly differ across molecular subgroups. The p53abn group showed a non-significant trend toward reduced overall survival while disease-free survival was similar among the groups. Conclusion: Routine IHC assessment is a practical approach to identify molecular subtypes, particularly MMRd tumors that may benefit from immunotherapy, and p53abn tumors that may warrant intensified treatment strategies.
No takes yet. Share an insight, caveat, or question.
Güleç et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: